10 research outputs found
Common Variants in Alzheimer’s Disease and Risk Stratification by Polygenic Risk Scores
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n=409,435 and validation size n=58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease.The present work has been performed as part of the doctoral program of I. de Rojas at the
Universitat de Barcelona (Barcelona, Spain) supported by national grant from the
Instituto de Salud Carlos III FI20/00215. The Genome Research @ Fundació ACE project
(GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE,
and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA
Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects
(grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by
national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301.
Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and
funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación
and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer
Europa”). The Alzheimer Center Amsterdam is supported by Stichting
Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was
developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control
samples was performed in the context of EADB (European Alzheimer DNA biobank)
funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). 100-Plus
study. This work was supported by Stichting Alzheimer
Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel
(ZonMW project number 733050814, 733050512) and Stichting VUmc Fonds. Genotyping of the 100-Plus Study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project numb 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a
grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of LongTerm Care. This work was supported by a
grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND) and also funded by Inserm, Institut Pasteur de
Lille, the Lille Métropole Communauté Urbaine, the French government’s LABEX
DISTALZ program (development of innovative strategies for a transdisciplinary
approach to AD). Genotyping of the German case-control samples was performed in the
context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND
(German Federal Ministry of Education and Research, BMBF: 01ED1619A). The i–Select chips was funded by the French National Foundation on AD and
related disorders. EADI was supported by the LABEX (laboratory of excellence program
investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université
de Lille 2 and the Lille University Hospital. GERAD was supported by the Medical
Research Council (Grant n° 503480), Alzheimer’s Research UK (Grant n° 503176), the
Wellcome Trust (Grant n° 082604/2/07/Z) and German Federal Ministry of Education
and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102,
01GI0711, 01GI0420. CHARGE was partly supported by the NIA/NHLBI grants
AG049505, AG058589, HL105756 and AGES contract N01–AG–12100, the Icelandic
Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was
supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and
the Alzheimer’s Association grant ADGC–10–19672
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease.Peer reviewe
Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease.
Late onset Alzheimer's disease is the most common form of dementia for which about 30 susceptibility loci have been reported. The aim of the current study is to identify novel genes associated with Alzheimer's disease using the largest up-to-date reference single nucleotide polymorphism (SNP) panel, the most accurate imputation software and a novel gene-based analysis approach which tests for patterns of association within genes, in the powerful genome-wide association dataset of the International Genomics of Alzheimer's Project Consortium, comprising over 7 million genotypes from 17,008 Alzheimer's cases and 37,154 controls. In addition to earlier reported genes, we detected three novel gene-wide significant loci PPARGC1A (p = 2.2 × 10-6), RORA (p = 7.4 × 10-7) and ZNF423 (p = 2.1 × 10-6). PPARGC1A and RORA are involved in circadian rhythm; circadian disturbances are one of the earliest symptoms of Alzheimer's disease. PPARGC1A is additionally linked to energy metabolism and the generation of amyloid beta plaques. RORA is involved in a variety of functions apart from circadian rhythm, such as cholesterol metabolism and inflammation. The ZNF423 gene resides in an Alzheimer's disease-specific protein network and is likely involved with centrosomes and DNA damage repair
Recommended from our members
Gene-Based Analysis in HRC Imputed Genome Wide Association Data Identifies Three Novel Genes For Alzheimer’s Disease
A novel POLARIS gene-based analysis approach was employed to compute gene-based polygenic risk score (PRS) for all individuals in the latest HRC imputed GERAD (N cases=3,332 and N controls=9,832) data using the International Genomics of Alzheimer’s Project summary statistics (N cases=13,676 and N controls=27,322, excluding GERAD subjects) to identify the SNPs and weight their risk alleles for the PRS score. SNPs were assigned to known, protein coding genes using GENCODE (v19). SNPs are assigned using both 1) no window around the gene and 2) a window of 35kb upstream and 10kb downstream to include transcriptional regulatory elements. The overall association of a gene is determined using a logistic regression model, adjusting for population covariates. Three novel gene-wide significant genes were determined from the POLARIS gene-based analysis using a gene window; PPARGC1A, RORA and ZNF423 . The ZNF423 gene resides in an Alzheimer’s disease (AD)-specific protein network which also includes other AD-related genes. The PPARGC1A gene has been linked to energy metabolism and the generation of amyloid beta plaques and the RORA has strong links with genes which are differentially expressed in the hippocampus. We also demonstrate no enrichment for genes in either loss of function intolerant or conserved noncoding sequence regions
Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer’s disease
A novel POLARIS gene-based analysis approach was employed to compute gene-based polygenic risk score (PRS) for all individuals in the latest HRC imputed GERAD (N cases=3332 and N controls=9,832) data using the International Genomics of Alzheimer's Project summary statistics (N cases=13676 and N controls= 27322, excluding GERAD subjects) to identify the SNPs and weight their risk alleles for the PRS score. SNPs were assigned to known, protein coding genes using GENCODE (v19). SNPs are assigned using both 1) no window around the gene and 2) a window of 35kb upstream and 10kb downstream to include transcriptional regulatory elements. The overall association of a gene is determined using a logistic regression model, adjusting for population covariates. Three novel gene wide significant genes were determined for the POLARIS gene-based analysis using a gene window; PPARGC1A, RORA and ZNF423. The ZNF432 gene resides in an Alzheimer's disease (AD) specific protein network which also includes other AD-related genes. The PPARGC1A gene has been linked to energy metabolism and the generation of amyloid beta plaques and the RORA has strong links with genes which are differentially expressed in the hippocampus. We also demonstrate no enrichment for genes in either loss of function intolerant or conserved noncoding sequence regions
Common polygenic variation enhances risk prediction for Alzheimer's disease.
Background: The identification of subjects at high risk for Alzheimer’s disease is important for prognosis and early intervention. We investigated the polygenic architecture of Alzheimer’s disease (AD) and the accuracy of AD prediction models, including and excluding the polygenic component in the model.
Methods: This study used genotype data from the powerful dataset comprising 17,008 cases and 37,154 controls obtained from the International Genomics of Alzheimer’s Project (IGAP). Polygenic score analysis tested whether the alleles identified to associate with disease in one sample set were significantly enriched in the cases relative to the controls in an independent sample. The disease prediction accuracy was investigated by means of sensitivity, specificity, Area Under the receiver operating characteristic Curve (AUC) and positive predictive value (PPV).
Results: We observed significant evidence for a polygenic component enriched in Alzheimer’s disease (p=4.9x10-26). This enrichment remained significant after APOE and other genome-wide associated regions were excluded (p=3.4x10 19). The best prediction accuracy AUC=78% was achieved by a logistic regression model with APOE, the polygenic score as predictors and age. When looking at the genetic component only, the PPV was 81%, increasing to 82% when age was added as a predictor. Setting the total normalised polygenic score of greater than 0.91, the positive predictive value has reached 90%.
Conclusion: Polygenic score has strong predictive utility of Alzheimer’s disease risk and is a valuable research tool in experimental designs, e.g. for selecting Alzheimer’s disease patients into clinical trials
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease.</p
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease. © 2021, The Author(s)
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease. © 2021, The Author(s)